

Supplemental Table 1. Treatment regimen at the time of scan 1 and scan 2\*

Subject	Systemic therapy
1	Anti-androgen (bicalutamide), GnRH analog (leuprolide), denosumab
2	Anti-androgen (bicalutamide), GnRH analog (triptorelin)
3	Anti-androgen (enzalutamide), GnRH analog (leuprolide)
4	Docetaxel, GnRH analog (leuprolide), denosumab
5	GnRH analog (triptorelin), zoledronate
6	GnRH analog (triptorelin), denosumab
7	Anti-androgen (enzalutamide), GnRH analog (triptorelin), zoledronate
8	GnRH analog (triptorelin), denosumab
9	Anti-androgen (enzalutamide), GnRH analog (leuprolide), denosumab
10	GnRH analog (leuprolide), denosumab
11	GnRH analog (leuprolide),
12	GnRH analog (leuprolide), denosumab
13	Anti-androgen (enzalutamide), GnRH analog (leuprolide), denosumab
14	(bilateral orchiectomy)

- 15 Abiraterone, GnRH analog (leuprolide)
- 16 Anti-androgen (enzalutamide), GnRH analog (leuprolide), denosumab
- 17 GnRH analog (leuprolide)
- 18 GnRH analog (leuprolide)

---

\*GnRH, gonadotropin-releasing hormone

SUPPLEMENTAL TABLE 2. Repeatability between scanner type for SUV<sub>max</sub>\*†

Organ or lesion	Siemens mCT (n = 11 subjects)		Siemens Biograph Truepoint (n = 7 subjects)		
	SUV <sub>max</sub>		SUV <sub>max</sub>		
	n	wCV (%)	n	wCV (%)	<i>P</i>
Parotid glands	22	9.7	14	9.3	0.64
Submandibular glands	22	10.7	14	9.3	0.55
Spleen	11	10.9	7	7.1	0.52
Bone lesions, total	51	11.4	48	12.1	0.28
Location					
Extremity	12	11.0	8	8.9	0.73
Pelvic	12	6.6	13	11.2	0.06
Skull	6	11.2	3	16.2	0.60
Thoracic	11	12.0	12	12.9	0.47
Vertebrae	10	14.3	12	10.3	0.66
Nodal lesions	21	10.9	6	9.3	0.85
Prostate/bed	4	12.0	3	5.6	0.21

\*SUV, standardized uptake value; wCV, within-subject coefficient of variation

†Visceral lesions were excluded from analysis due to their small number and only being present in the cohort imaged on the mCT.

SUPPLEMENTAL TABLE 3. Repeatability between scanner type for SUV<sub>mean</sub>\*†

Organ or lesion	Siemens mCT (n = 11 subjects)		Siemens Biograph Truepoint (n = 7 subjects)		
	SUV <sub>mean</sub>		SUV <sub>mean</sub>		<i>P</i>
	n	wCV (%)	n	wCV (%)	
Parotid glands	22	9.4	14	9.3	0.97
Submandibular glands	22	8.0	14	10.1	0.31
Spleen	11	12.1	7	6.1	0.35
Bone lesions, total	51	10.6	48	10.4	0.28
Location					
Extremity	12	15.4	8	10.7	0.36
Pelvic	12	9.9	13	10.1	0.59
Skull	6	8.3	3	13.4	0.51
Thoracic	11	6.4	12	8.5	0.29
Vertebrae	10	9.5	12	9.0	0.86
Nodal lesions	21	11.4	6	9.7	0.95
Prostate/bed	4	4.8	3	9.2	0.11

\*SUV, standardized uptake value; wCV, within-subject coefficient of variation

†Visceral lesions were excluded from analysis due to their small number and only being present in the cohort imaged on the mCT